Cannabinoids reduce insomnia severity and improve sleep quality in adults with insomnia or poor sleep quality
This meta-analysis of 10 RCTs (2134 participants) found that cannabinoids significantly reduced insomnia severity (MD -3.73, 95% CI -5.04 to -2.42) and improved sleep quality (MD -3.94, 95% CI -5.47 to -2.40). Total sleep time increased by 33.99 minutes and sleep efficiency improved by 4.31%, with modest reductions in sleep onset latency. Adverse events were more frequent with cannabinoids (RR 3.96) but mostly mild and no serious harms were observed.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Cannabinoids reduce insomnia severity and improve sleep quality in adults with insomnia or poor sleep quality The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 49/100 (low).
The Claim
Cannabinoids reduce insomnia severity and improve sleep quality in adults with insomnia or poor sleep quality
This conclusion is most relevant to: Adults with insomnia or poor sleep quality.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Efficacy of cannabinoids for insomnia and sleep disturbance: A systematic review and meta-analysis of randomized controlled trials. (Sleep medicine, 2026) —
How It Works
The proposed biological pathway:
- ▸Cannabinoids interact with the endocannabinoid system, which regulates sleep-wake cycles
- ▸They may modulate neurotransmitter release (e.g., GABA, serotonin) involved in sleep promotion
- ▸Cannabinoids may reduce anxiety and pain, which are common contributors to insomnia
- ▸Result: Improved sleep quality and duration
Who Might Benefit
Evidence fit by population:
- ▸Adults with insomnia or poor sleep quality
Recommended Dose
N/A (not specified in abstract)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Limited number of RCTs (10) and potential heterogeneity in cannabinoid types and doses
- ▸Short-term follow-up; long-term efficacy and safety not established
- ▸Adverse events more frequent with cannabinoids, though mild
- ▸Optimal dosing and formulation not defined
Frequently Asked Questions
What types of cannabinoids were studied?▼
The abstract does not specify the exact types (e.g., THC, CBD, or combinations), but they were compared to placebo or melatonin.
How much did sleep improve?▼
Insomnia severity decreased by about 3.7 points on the ISI, sleep quality improved by about 3.9 points on the PSQI, and total sleep time increased by about 34 minutes.
Are there any side effects?▼
Yes, adverse events were more common with cannabinoids (risk ratio 3.96), mostly mild dizziness and dry mouth, with no serious harms reported.
Is this a recommendation to use cannabinoids for insomnia?▼
The authors suggest cannabinoids may be a potential alternative, but larger, long-term trials are needed to define optimal dosing and sustained efficacy.
References
- 1.Asim R, Azeem B, Wijdan SA, Hanafi MA, Mubarika M, Muneer SU, Abdalla MI, Ishtiaq S, Ashraf H. “Efficacy of cannabinoids for insomnia and sleep disturbance: A systematic review and meta-analysis of randomized controlled trials..” Sleep medicine, 2026. PMID: 42574897 DOI: 10.1016/j.sleep.2026.109193